2 registrations that name SS-31 as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 2 registrations
Status
Phase
2US sites across 2 states
1
2 to 4
5 to 19
20 or more
All 2 registrations
RecruitingNCT07531251
Clinical Trial in Patients With Barth Syndrome- 4TAZPower
Phase 4
Stealth BioTherapeutics Inc.
About 48 people
Started Jul 2, 2026
In plain words A Phase 4 study of SS-31 in male participants 5 to 55, run by Stealth BioTherapeutics Inc.. It plans to enroll about 48 people at 3 sites, 1 of them in the US.
Who it lists and where
Who the trial lists, as registered
Lists male participants 5 to 55. Conditions: Barth Syndrome.
Willing and able to provide signed informed consent form (ICF) prior to participation in any trial-related procedures.
Agrees to adhere to the trial requirements for the length of the trial.
Must have genetically confirmed Barth Syndrome (pathogenic variant in the TAZ gene)
Male aged ≥ 5 years at time of the Screening Visit
16 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Elamipretide; Placebo
Registered summary
Phase 3b/4, randomized, double-blind, parallel-group, placebo-controlled clinical trial to evaluate the efficacy, safety, and pharmacokinetics of a once daily SC injection of elamipretide in subjects with genetically confirmed BTHS for 72 weeks. The primary trial objective is to confirm the efficacy of elamipretide which is approved in the United States(FORZINITY™) under the accelerated approval based on an improvement in knee extensor muscle strength, an intermediate clinical endpoint.
Where, as registered
1 US site in 1 state; also Canada (1), United Kingdom (1).
RecruitingNCT07275424
Study of Healthy Aging and Physical Function With Elamipretide
Phase 2
David Marcinek
About 30 people
Started Nov 26, 2025
In plain words A Phase 2 study of SS-31 in people 65 to 80, run by David Marcinek. It plans to enroll about 30 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 65 to 80; healthy volunteers accepted. Conditions: Aging, Healthy.
Male or female aged ≥65 and ≤80 years
VO2peak ≤ 37.3ml/kg/min for men and ≤ 25.7ml/kg/min for women as evidence of lower mitochondrial function
Are ambulatory and able to perform activities of daily living without assistance
Have sufficient venous access for clinical blood draw
8 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Elamipretide will be supplied as a sterile 5.0 mL single-patient, multi-dose glass vial containing 3.75 mL of elamipretide solution (elamipretide [80 mg/mL], phosphate buffer, and benzyl alcohol)
Registered summary
This study will utilize a daily dose of elamipetide for 4 weeks and will screen a sufficient number of subjects for 30 subjects to enroll in the study. The planned duration of the study includes baseline measurement, followed by 4 weeks intervention period, a midpoint (2week ±3days) check-in phone interview, and post intervention visits that mirror the baseline visits. After the last injection, subjects will enter the 2-week follow-up period, concluded by the end-of-study contact.